EMA Authorised: Oslif Breezhaler (indacaterol maleate) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Oslif Breezhaler (indacaterol maleate) for chronic obstructive pulmonary disease; decision date 18 November 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Oslif Breezhaler (indacaterol maleate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 18/11/2025